The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Bayer Schering Pharma; Janssen; Novartis; Roche
Speakers' Bureau - Amgen; Bayer Schering Pharma; Janssen; Novartis; Roche
Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
 
Nicolaas Lumen
Honoraria - AstraZeneca; Janssen; Lilly
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ipsen (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen
 
Simon Chowdhury
Consulting or Advisory Role - Janssen
Speakers' Bureau - Astellas Pharma; Janssen; Sanofi
 
Alison J. Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Janssen Oncology; Roche; Sanofi
 
Anders Bjartell
Stock and Other Ownership Interests - WntResearch
Honoraria - Astellas Pharma
Consulting or Advisory Role - EXINI Diagnostics
Speakers' Bureau - Astellas Pharma; Bayer
Patents, Royalties, Other Intellectual Property - Glactone
 
Luis Costa
Speakers' Bureau - Janssen
 
Susan Feyerabend
No Relationships to Disclose
 
Luca Galli
No Relationships to Disclose
 
Ewa Kalinka-Warzocha
Leadership - Centrum Onkologii Instytutu (I)
Honoraria - Acraf; Acraf (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Janssen; Janssen (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Consulting or Advisory Role - Acraf; Acraf (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Janssen; Janssen (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Research Funding - Bayer; Bayer (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Janssen; Janssen (I); Merck; Merck (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb (I); MSD; MSD (I); Roche; Roche (I)
 
Gero Kramer
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Ipsen; Janssen; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
 
Pablo Maroto
No Relationships to Disclose
 
Vsevolod B Matveev
No Relationships to Disclose
 
Thomas Paiss
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Janssen-Cilag
 
Salvatore Pisconti
No Relationships to Disclose
 
Dominique Spaeth
Honoraria - Amgen; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; Pfizer; Roche; Sanofi
Research Funding - Chugai Pharma; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Novartis; Pierre Fabre; Roche; Sanofi
 
Francisco Gomez Veiga
No Relationships to Disclose
 
Laurent Antoni
Employment - Janssen
 
Edwin Klumper
Consulting or Advisory Role - Janssen
 
Robert Wapenaar
Employment - Janssen-Cilag
Stock and Other Ownership Interests - Johnson & Johnson
 
Florence Thoret-Bauchet
Employment - Janssen
 
Emma Lee
Employment - Janssen
Stock and Other Ownership Interests - Janssen